Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
Official title: A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
282
Start Date
2025-06
Completion Date
2027-05
Last Updated
2025-03-27
Healthy Volunteers
No
Conditions
Interventions
QLG2128
Recommended dosage is 80 μg subcutaneously once daily,52week
Teriparatide Injection
Recommended dosage is 20μg subcutaneously once daily,52week